- Report
- October 2024
- 185 Pages
Global
From €3312EUR$3,545USD£2,802GBP
€3680EUR$3,939USD£3,113GBP
- Report
- April 2025
- 50 Pages
Global
From €2476EUR$2,650USD£2,094GBP
- Report
- June 2020
- 753 Pages
Global
From €2775EUR$2,970USD£2,347GBP
€3083EUR$3,300USD£2,608GBP
Fadrozole is an aromatase inhibitor used in the treatment of breast cancer. It is used to reduce the amount of estrogen in the body, which can help slow the growth of certain types of breast cancer cells. Fadrozole is typically used in combination with other drugs, such as tamoxifen, to treat advanced breast cancer. It is also used to reduce the risk of recurrence in postmenopausal women who have already been treated for early-stage breast cancer.
The Fadrozole market is a subset of the larger oncology drugs market. It is a highly competitive market, with many companies offering their own versions of the drug. Companies in the Fadrozole market include AstraZeneca, Pfizer, Novartis, and Teva Pharmaceuticals. Show Less Read more